Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Kura Oncology (KURA – Research Report). The associated price target remains the same with $24.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charles Zhu has given his Buy rating due to a combination of factors that highlight Kura Oncology’s strategic advancements and potential market opportunities. The initiation of the Phase 1 KOMET-015 trial, which involves dosing patients with a combination of ziftomenib and imatinib for advanced GIST, marks a significant step in exploring new treatment avenues. This trial is notable as it is the first to investigate a menin inhibitor alongside standard care therapy for GIST, potentially offering a complementary approach to existing treatments that focus on secondary KIT resistance.
Furthermore, Kura Oncology’s partnership with Kyowa Kirin underscores the company’s commitment to expanding its commercial reach beyond AML, with potential financial benefits from opt-in payments. The estimated patient population for GIST in the US, particularly those resistant to imatinib, presents a substantial addressable market. Additionally, Kura’s financial position, with a cash runway of approximately 2.5 years, supports its ongoing research and development efforts, further justifying the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.